Fresenius Kabi introduces leucovorin calcium injection
Fresenius Kabi is launching leucovorin calcium injection, a medication indicated to counteract the toxicity and diminish side effects of impaired methotrexate elimination.
Leucovorin calcium also is used as a rescue drug after high-dose methotrexate therapy in osteosarcoma in the treatment of megaloblastic anemia due to folic acid deficiency when oral therapy is not feasible, as well as in combination with 5-fluorouracil to prolong survival in the palliative treatment of patients with advanced colorectal cancer.
Fresenius Kabi’s product is available in 10 mg per ml single-use vials, 100 mg per 10 ml and 500 mg per 50 ml strengths.
This is the only liquid presentation of leucovorin available in the United States, the company said.
“We are pleased to offer a version of leucovorin calcium injection that eliminates the need for reconstitution, providing pharmacists an efficient way to prepare this medication,” Fresenius Kabi USA president and CEO John Ducker said.
Leucovorin calcium also is used as a rescue drug after high-dose methotrexate therapy in osteosarcoma in the treatment of megaloblastic anemia due to folic acid deficiency when oral therapy is not feasible, as well as in combination with 5-fluorouracil to prolong survival in the palliative treatment of patients with advanced colorectal cancer.
Fresenius Kabi’s product is available in 10 mg per ml single-use vials, 100 mg per 10 ml and 500 mg per 50 ml strengths.
This is the only liquid presentation of leucovorin available in the United States, the company said.
“We are pleased to offer a version of leucovorin calcium injection that eliminates the need for reconstitution, providing pharmacists an efficient way to prepare this medication,” Fresenius Kabi USA president and CEO John Ducker said.